The role of HE4 in ovarian cancer: Inhibiting tumour cell proliferation and metastasis

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1645-1660

  Gao, L ^a   Cheng, H Y ^a   Dong, L ^a   Ye, X ^a   Liu, Y N ^a   Chang, X H ^a   Cheng, Y X ^a   Chen, J ^a   Ma, R Q ^a   Cui, Heng ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; Cell Proliferation; Human Epididymis Protein 4 (HE4); Metastasis; Ovarian Cancer

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BENIGN TUMOR; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EPITHELIUM CELL; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN EPIDIDYMIS PROTEIN 4 GENE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TUMOR GENE; TUMOR XENOGRAFT;

EID: 80155130050     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900507     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Suh KS, Park SW, Castro A, et al: Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn 2010; 10: 1069-1083.
3. Bast RC Jr: Status of tumour markers in ovarian cancer screening. J Clin Oncol 2003; 21(10 suppl): 200S-205S.
4. Dutta S, Wang FQ, Fishman DA: The dire need to develop a clinically validated screening 4 method for the detection of early-stage ovarian cancer. Biomark Med 2010; 4: 437-439.
5. Kirchhoff C, Habben I, Ivell R, et al: A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991; 45: 350-357.
6. Kirchhoff C: Molecular characterization of epididymal proteins. Rev Reprod 1998; 3: 86-95.
7. Drapkin R, von Horsten HH, Lin Y, et al: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162-2169.
8. Galgano MT, Hampton GM, Frierson HF Jr: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847-853.
9. Lamy PJ, Roques S, Viglianti C, et al: HE4, a novel marker for epithelial ovarian cancer: evaluation of analytical performances. Ann Biol Clin (Paris) 2010; 68: 325-329 [in French, English abstract].
10. Hellström I, Heagerty PJ, Swisher EM, et al: Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett 2010; 296: 43-48.
11. Yamashita S, Tokuishi K, Hashimoto T, et al: Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol 2011; 32: 265-271.
12. Bingle L, Cross SS, High AS, et al: WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006; 7: 61.
13. Moore RG, Brown AK, Miller MC, et al: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008; 110: 196-201.
14. Hegmans JP, Veltman JD, Fung ET, et al: Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDITOF MS. Technol Cancer Res Treat 2009; 8: 323-332.
15. Winstead ER: Ovarian cancer markers validated for early detection. NCI Cancer Bulletin 2009; 6(number 8): (available at: www.cancer.gov/ncicancerbulletin/042109/page2).
16. Scholler N, Crawford M, Sato A, et al: Beadbased ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 2006; 12: 2117-2124.
17. Huhtinen K, Suvitie P, Hiissa J, et al: Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315-1319.
18. Montagnana M, Lippi G, Danese E, et al: Usefulness of serum HE4 in endometriotic cysts. Br J Cancer 2009; 101: 548.
19. Anastasi E, Marchei GG, Viggiani V, et al: HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010; 31: 113-119.
20. Köbel M, Kalloger SE, Boyd N, et al: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5: e232.
21. Berry NB, Cho YM, Harrington MA, et al: Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol 2004; 92: 896-904.
22. Yurkovetsky Z, Skates S, Lomakin A, et al: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159-2166.
23. Anderson GL, McIntosh M, Wu L, et al: Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010; 102: 26-38.
24. Dong L, Chang XH, Ye X, et al: The values of serum human epididymis secretory protein 4 and CA125 assay in the diagnosis of ovarian malignancy. Zhonghua Fu Chan Ke Za Zhi (China) 2008; 43: 931-936 [in Chinese, English abstract].
25. Chang X, Ye X, Dong L, et al: Human epididymis protein 4 (HE4) as a serum tumor bio marker in patients with ovarian carcinoma. Int J Gynecol Cancer 2011; 21: 852-858.
26. Liu Y, Ye X, Cheng H, et al: Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors. Zhonghua Fu Chan Ke Za Zhi 2010; 45: 363-366 [in Chinese, English abstract].
27. Hellström I, Raycraft J, Hayden-Ledbetter M, et al: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-3700.
28. Moore RG, McMeekin DS, Brown AK, et al: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40-46.
29. Maines-Bandiera SL, Kruk PA, Auersperg N: Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 1992; 167: 729-735.
30. Chen L (ed): Diagnostic Gynecologic and Obstetric Pathology, 2nd edn. Beijing: People's Military Medical Press, 2010; pp 268-394.
31. Kaku T, Ogawa S, Kawano Y, et al: Histological classification of ovarian cancer. Med Electron Microsc 2003; 36: 9-17.
32. Moore RG, Brown AK, Miller MC, et al: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108: 402-408.
33. Clauss A, Lilja H, Lundwall A: The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun 2005; 333: 383-389.
34. Bouchard D, Morisset D, Bourbonnais Y, et al: Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 167-174.
35. Clauss A, Lilja H, Lundwall A: A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002; 368: 233-242.
36. Bingle L, Singleton V, Bingle CD: The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002; 21: 2768-2773.
37. Devoogdt N, Revets H, Ghassabeh GH, et al: Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci 2004; 1028: 380-389.
38. Hu Y, Sun H, Drake J, et al: From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res 2004; 64: 7748-7755.
39. Tian X, Shigemasa K, Hirata E, et al: Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep 2004; 12: 1001-1006.
40. Taggart CC, Greene CM, McElvaney NG, et al: Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IlBBBdegradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002; 277: 33648-33653.
41. Sung J, Turner J, McCarthy S, et al: Oncogene regulation of tumor suppressor genes in tumorigenesis. Carcinogenesis 2005; 26: 487-494.
42. Li Y, Sarkar FH: Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 2002; 132: 3623-3631.
43. Liang G, Gonzales FA, Jones PA, et al: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2i-deoxycytidine. Cancer Res 2002; 62: 961-966.
44. Westin U, Nyström M, Ljungcrantz I, et al: The presence of elafin, SLPI, IL1-RA and STNFppRI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm 2002; 11: 7-12.